Systematic Review of Gossypol/at-101 in Cancer Clinical Trials


Institutional Review Board Statement



Download 2,34 Mb.
Pdf ko'rish
bet19/23
Sana04.05.2023
Hajmi2,34 Mb.
#934966
1   ...   15   16   17   18   19   20   21   22   23
Bog'liq
Systematic Review of GossypolAT-101 in Cancer Clin

Institutional Review Board Statement:
Not applicable.
Informed Consent Statement:
Not applicable.
Data Availability Statement:
No new data were created or analyzed in this study. Data sharing is
not applicable to this article.
Acknowledgments:
We would like to thank Monika Schumacher for editorial assistance.
Conflicts of Interest:
The authors declare that they have no conflict of interest.
Abbreviations
ADT
androgen deprivation therapy
AE
adverse events
AIF
apoptosis-inducing factor
ALT
alanine aminotransferase
APE1/Ref-1
apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1
AST
aspartate aminotransferase
AUC
area under the concentration time curve
BID
latin: bis in die; twice a day
Bcl-2
B-cell lymphoma 2
BH3
Bcl-2 homology domain 3
CEA
carcinoembryonic antigen
CHD1
chromodomain helicase DNA-binding protein
co
control
cCR
clinical complete response
CR
complete response
CRPC
castrate-resistant prostate cancer
CTCAE
Common Terminology Criteria for Adverse Events
CXCL8
chemokine C-X-C motif ligand 8
DCR
disease control rate
DLT
dose-limiting toxicity
DNA
deoxyribonucleic acid
ECG
electrocardiogram
ECOG
Eastern Cooperative Oncology Group
eg
experimental group
EGFR
epidermal growth factor receptor
ES-SCLC
extensive stage—small cell lung cancer
GEC
gastroesophageal carcinoma
GI
gastrointestinal
HDAC
histone deacetylase
HDACi
histone deacetylase inhibitor
HNSCC
head and neck squamous cell carcinoma
IL-8
interleukin-8
IV
intravenously
LHRH
luteinizing hormone-releasing hormone
MOMP
mitochondrial outer membrane permeabilization
mOS
median overall survival
mPFS
median progression-free survival
MR
minor response
MTD
maximally tolerated dose
n. a.
not available
ORR
objective response rate
OR
objective response
OS
overall survival


Pharmaceuticals
2022
,
15
, 144
28 of 33
P-gp
p-glycoprotein
PBMC
peripheral blood mononuclear cell
PCWG
Prostate Cancer Clinical Trials Working Group
PD
progressive disease
PFS
progression-free survival
PO BID
latin: per os bis in die; orally, twice a day
PO QD
latin: per os quaque die; orally, once a day
PR
Download 2,34 Mb.

Do'stlaringiz bilan baham:
1   ...   15   16   17   18   19   20   21   22   23




Ma'lumotlar bazasi mualliflik huquqi bilan himoyalangan ©hozir.org 2024
ma'muriyatiga murojaat qiling

kiriting | ro'yxatdan o'tish
    Bosh sahifa
юртда тантана
Боғда битган
Бугун юртда
Эшитганлар жилманглар
Эшитмадим деманглар
битган бодомлар
Yangiariq tumani
qitish marakazi
Raqamli texnologiyalar
ilishida muhokamadan
tasdiqqa tavsiya
tavsiya etilgan
iqtisodiyot kafedrasi
steiermarkischen landesregierung
asarlaringizni yuboring
o'zingizning asarlaringizni
Iltimos faqat
faqat o'zingizning
steierm rkischen
landesregierung fachabteilung
rkischen landesregierung
hamshira loyihasi
loyihasi mavsum
faolyatining oqibatlari
asosiy adabiyotlar
fakulteti ahborot
ahborot havfsizligi
havfsizligi kafedrasi
fanidan bo’yicha
fakulteti iqtisodiyot
boshqaruv fakulteti
chiqarishda boshqaruv
ishlab chiqarishda
iqtisodiyot fakultet
multiservis tarmoqlari
fanidan asosiy
Uzbek fanidan
mavzulari potok
asosidagi multiservis
'aliyyil a'ziym
billahil 'aliyyil
illaa billahil
quvvata illaa
falah' deganida
Kompyuter savodxonligi
bo’yicha mustaqil
'alal falah'
Hayya 'alal
'alas soloh
Hayya 'alas
mavsum boyicha


yuklab olish